5PSQ-050 Neuropsychiatric adverse effects on dolutegravir: experience in a third-level hospital

BACKGROUND: Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is currently among the most commonly used antiretroviral agents. Recent reports have raised concerns about their safety, especially with regard to neuropsychiatric adverse effects (neuropsychiatric AEs)....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur J Hosp Pharm
Autores principales: Lopez, TLopez Viñau, de Molina, MD López Malo, de Vicente, M Sáez-Torres, Donoso, J López-Santamaria, Torres, IReyes, Parada, J Hernández
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Group 2018
Materias:
Section 5: Patient safety and quality assurance
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535272/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.404
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares